PROM1 and precursor B-cell acute lymphoblastic leukemia: We next comparatively analyzed the expression of CD133 and other commonly described B-ALL targets related to disease pathophysiology and/or serving for therapeutic approaches on leukemic cells in our B-ALL patient cohort (Table 1), and we analyzed the potential correlations (Figure 4A).